Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Abiomed, Inc.    ABMD

ABIOMED, INC.

(ABMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The stock is in a well-established, long-term rising trend above the technical support level at 199.74 USD
Weaknesses
  • With an expected P/E ratio at 60.28 and 54.62 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart
Sector Advanced Medical Equipment & Technology - NEC
1st jan.Capitalisation (M$)Investor Rating
ABIOMED, INC.56.42%12 319
THERMO FISHER SCIENTIFIC46.89%188 109
DANAHER CORPORATION46.23%159 430
INTUITIVE SURGICAL, INC.32.00%100 551
SHENZHEN MINDRAY BIO-MEDICA..92.41%65 154
EDWARDS LIFESCIENCES CORPOR..10.28%53 450
SIEMENS HEALTHINEERS AG-7.11%51 688
ILLUMINA, INC.5.70%51 196
BOSTON SCIENTIFIC CORPORATI..-23.91%49 272
KONINKLIJKE PHILIPS N.V.1.08%47 587
AGILENT TECHNOLOGIES, INC.34.98%35 236
RESMED, INC.33.83%30 387
OLYMPUS CORPORATION40.20%29 217
CERNER CORPORATION1.23%22 777
HOLOGIC, INC.40.12%18 802
VARIAN MEDICAL SYSTEMS, INC..22.99%15 956
More Results
Financials (USD)
Sales 2021 834 M - -
Net income 2021 206 M - -
Net cash 2021 549 M - -
P/E ratio 2021 60,3x
Yield 2021 -
Capitalization 12 319 M 12 319 M -
EV / Sales 2021 14,1x
EV / Sales 2022 11,5x
Nbr of Employees 1 536
Free-Float 92,2%
Upcoming event on ABIOMED, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes